The next chapter of the Event Horizon saga is officially unfolding in the comics. After the massive success of the prequel miniseries Event Horizon: Dark Descent, IDW has dropped a sequel set 200 ...

In the heart of Cap Ferret – a quaint oyster village situated on France’s west coast often dubbed the French Hamptons – Hôtel Villa Colette has just opened its doors, marking the first outpost of the ...

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

From the Capital of France to the Capital of New York -- a cutting-edge biotech firm that uses AI to research cancer treatments has chosen Albany for its first home outside of Paris. It will be ...

ALBANY, NY (NEWS10) — From the capital of France to the capital of New York — a cutting-edge biotech firm that uses AI to research cancer treatments has chosen Albany for its first home outside of ...

The Spanish government has announced a goal to raise a $200 million venture capital fund as part of a biotech initiative focused on Boston. The partnership aims to “build bridges” with the Boston ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures. According to an analysis of Fierce Biotech’s layoff data, a total ...

After 2024 marked the return of the biotech megaround, 2025 proved it wasn’t just a one-year anomaly. Last year was characterized by fewer but larger venture capital financings for biotech, with ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...